Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus with Cyclosporine Discontinuation vs Minimization in Kidney Transplant
NCT00154284Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2005
- Primary completion
- Jul 2008
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of everolimus in kidney transplant rejection (2 arms), sponsored by Novartis. Primary endpoint: Renal Function Measured by Calculated Glomerular Filtration Rate at 12 months. Started Jul 2005; status: completed.
02
Drugs
everolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00154284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00154284.